TrumpRx’s addition of 600 generics to its comparison platform could reshape how patients shop for medicines by increasing transparency and pushing pharmacies to compete more aggressively on cost.
“Wellness buyers” skew wealthy: Targeting affluent consumers may boost short-term margins, but it can limit scale and weaken long-term loyalty.
OTC brands drew far more video and ad views than Rx brands in April, capturing attention where health searches often begin.
Justices reject six pharma companies Medicare drug negotiation appeals, cementing federal discounts for consumers and tightening margins for pharma companies.
Most consumers still respond to healthcare ads despite skepticism, but brands can earn bigger wins with authentic storytelling and trusted medical voices.
A new lawsuit against OpenAI seeks to pause ChatGPT Health, raising odds of stricter safeguards and deeper reassessment of AI medical rollouts.
The Supreme Court ruling keeps remote mifepristone prescribing intact, reinforcing telehealth as essential healthcare infrastructure.
There’s a gap in usage and optimism, as nurses are more optimistic about AI improving care quality and outcomes.
The new FDA commissioner may scrutinize some of Makary’s outgoing programs, but initiatives like AI-driven drug reviews and tighter oversight of drug advertising are likely to continue.
Pharma execs detail strategies for gov’t pricing deals, countering vaccine skepticism, and driving D2C sales at FT’s US Pharma and Biotech Summit.
Healthcare costs now outrank even rising gas prices as consumers’ top financial concern, creating an opportunity for brands to offer short-term relief while longer-term solutions take shape.
Yet many consumers still engage with their content, pushing marketers to ensure their influencer partners have credibility.
Telehealth firms switching from compounded to brand-name GLP-1s must offer stronger patient support and expand into other high-demand treatments, like hormone therapies.
The medical society is proposing policies around bans, labels, and consent rules as fake physicians erode trust and risk patient harm.
AI can outperform doctors at some clinical tasks, but narratives overstating the tech’s advantages in patient care could erode physician trust.
More than half (53%) of patient groups view US drugmakers favorably, an 8-point drop since last year, tied to funding and engagement cuts.
FDA head Marty Makary is likely to be fired. While pharma’s relationship with him has been uneven, drugmakers may be even more concerned about Kennedy’s influence over his successor.
Google Health app will use device data and medical records to deliver health insights, intensifying competition among consumer health wearables and AI tools.
Fake health ads are flooding Facebook, meaning marketers must help consumers spot red flags like fake urgency, bogus logos, and so-called miracle cures.